Feasibility of the taylor vortex flow bioreactor for mesenchymal stromal cell expansion on microcarriers

Autor(es)

Gonzalez Gil, Liseth Viviana ^[1] ; Singh, Harminder ^[2] ; da Silva, Juliana de Sa ^[1] ; dos Santos, Diogo Peres ^[1] ; Covas, Dimas Tadeu ^[3] ; Swiech, Kamilla ^{[4, 3]} ; Torres Suazo, Claudio Alberto ^[1]

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Carlos, Chem Engn Dept, Sao Carlos, SP - Brazil

^[2] Univ Le Havre, Lab Waves & Complex Media, Le Havre - France

^[3] Univ Sao Paulo, Ctr Cell Based Therapy CTC, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto Med Sch, Ribeirao Preto, SP - Brazil

^[4] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Av Cafe S-N, BR-14040903 Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Biochemical Engineering Journal; v. 162, OCT 15 2020.
• Citações Web of Science: 0

Resumo

It is expected that a high cell volumetric concentration of human mesenchymal stromal cells (hMSCs) for cell therapy can be achieved by using scalable cell culture platforms as bioreactors. In this paper, the Taylor vortex flow bioreactor (TVFB) was evaluated for hMSCs expansion due to its potential to produce low and homogeneous hydrodynamic forces, which is important for the expansion of these cells. Thus, parameters such as volumetric coefficient of oxygen transfer and shear stress were estimated for the TVFB. Additionally, hMSCs cell expansion on microcarriers was evaluated in TVFB and compared with the traditional spinner flasks. Maximum shear stress and k(L)a were in the range of 0.027 - 0.065 Pa and 0.9-11.53 h(-1,) respectively, at rotation speed between 60 -120 rpm. Similar cell concentrations were obtained in both bioreactors, similar to 1.7 x 10(5) cells/mL, representing a fold increase of similar to 10 times. However, cell-microcarrier aggregates formed in the TVFB were smaller, with diameter of 0.36 +/- 0.01 mm compared to 0.75 +/- 0.31 mm obtained in the spinner flask, at the end of the culture. The results obtained in this study demonstrate the potential of TVFB to support manufacturing of anchorage dependent cell cultures for clinical applications. (AU)

• Processo FAPESP: 12/23228-4 - Expansão in vitro de células estromais mesenquimais e caracterização do secretoma: aplicações terapêuticas e biotecnológicas
• Beneficiário: Amanda Mizukami Martins
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
• Beneficiário: Dimas Tadeu Covas
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs